Ensysce Biosciences Inc (ENSC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has a cash flow conversion efficiency ratio of 1.767x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.96 Million) by net assets ($-1.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ENSC stock market capitalisation for the company's overall valuation and market capitalisation.
Ensysce Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ensysce Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ensysce Biosciences Inc ranked by their cash flow conversion efficiency. Explore ENSC cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Micronet Ltd
TA:MCRNT
|
-0.126x |
|
Seacera Group Bhd
KLSE:7073
|
-0.001x |
|
Polar Capital Holdings plc
LSE:POLR
|
0.460x |
|
Daekyo Co Ltd
KO:019685
|
0.035x |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
-0.771x |
|
Gold Mountain Ltd
AU:GMN
|
-0.080x |
|
Ceres Power Holdings PLC
LSE:CWR
|
-0.182x |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
-0.202x |
Annual Cash Flow Conversion Efficiency for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Ensysce Biosciences Inc from 2017 to 2025. View Ensysce Biosciences Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.88 Million | $-7.81 Million | -2.706x | -21.91% |
| 2024-12-31 | $3.38 Million | $-7.50 Million | -2.220x | -113.41% |
| 2023-12-31 | $-651.27K | $-10.78 Million | 16.552x | +272.89% |
| 2022-12-31 | $-4.03 Million | $-17.89 Million | 4.439x | +339.37% |
| 2021-12-31 | $-8.16 Million | $-8.24 Million | 1.010x | +439.31% |
| 2020-12-31 | $-6.66 Million | $-1.25 Million | 0.187x | +217.21% |
| 2019-12-31 | $186.17 Million | $10.99 Million | 0.059x | +1041.43% |
| 2018-12-31 | $197.39 Million | $-1.24 Million | -0.006x | -386.42% |
| 2017-12-31 | $195.27 Million | $-251.83K | -0.001x | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more